What factors predict a favorable outcome in young children with disseminated neuroblastoma? Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 5, 2006, Pages 242-243

  Kushner, Brian H ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hyperdiploidy; MYCN; Neuroblastoma; Pediatric; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG;

AGE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CORRELATION ANALYSIS; DIPLOIDY; DISSEMINATED CANCER; DOSE RESPONSE; GENETIC MARKER; HUMAN; LOW DRUG DOSE; NEUROBLASTOMA; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY;

EID: 33646696142     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0493     Document Type: Short Survey

References (4)

1. Schmidt ML et al. (2005) Favorable prognosis for patients 12-18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group study. J Clin Oncol 23: 6474-6480
2. London WB et al. (2005) The role of age in neuroblastoma risk stratification: The German, Italian, and Children's Oncology Group perspectives. Cancer Lett 228: 257-266
3. London WB et al. (2005) Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23: 6459-6465
4. Schmidt ML et al. (2000) Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 18: 1260-1268